<h2 dir="ltr"><strong>Graft Versus Host Disease</strong></h2>
<p dir="ltr"><a href="https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market">Graft Versus Host Disease</a> is an immune condition that occurs when immune cells after transplant procedures from the donor attack the recipient patient host&rsquo;s tissues; the disease is a side effect that is common after an allogeneic bone marrow transplant.</p>
<h3 dir="ltr"><strong>Graft Versus Host Disease Epidemiology Segmentation</strong></h3>
<ul>
<li dir="ltr" aria-level="1">Total Cases of GvHD</li>
<li dir="ltr" aria-level="1">Type-specific Cases of GvHD</li>
<li dir="ltr" aria-level="1">Acute GvHD Cases by Grading</li>
<li dir="ltr" aria-level="1">Acute GvHD Cases by Organ Involvement</li>
<li dir="ltr" aria-level="1">Chronic GvHD Cases by Grading</li>
<li dir="ltr" aria-level="1">Chronic GvHD Cases by Organ Involvement</li>
<li dir="ltr" aria-level="1">Total Treated Cases of GvHD</li>
<li dir="ltr" aria-level="1">Mortality Adjusted Treated Cases of GvHD</li>
</ul>
<h2 dir="ltr"><strong>Graft Versus Host Disease Epidemiology</strong></h2>
<ul>
<li dir="ltr" role="presentation">The total cases of GvHD in the 7MM were estimated at approximately 52K.</li>
<li dir="ltr" role="presentation">US - 43%</li>
<li dir="ltr" role="presentation">EU4 and the UK - 43%</li>
<li dir="ltr" role="presentation">Japan - 14%</li>
<li dir="ltr" role="presentation">The rise in cases of GvHD is driven by increased allogeneic stem cell transplants and improved post-transplant survival rates.</li>
<li dir="ltr" role="presentation">Acute GvHD cases by organ involvement in the US are segmented into the skin, liver, and gastrointestinal tract, with the highest cases (~3,600) affecting the skin and the lowest (~1,300) affecting the liver.</li>
</ul>
<h2 dir="ltr"><strong>Graft Versus Host Disease Market</strong></h2>
<ul>
<li dir="ltr" role="presentation">CAGR of 6.4% is predicted for the market during the forecast period (2026&ndash;2036).</li>
<li dir="ltr" role="presentation">The market size in the 7MM in 2025 was estimated at approximately USD 2.1 billion.</li>
<li dir="ltr" role="presentation">US - 77%</li>
<li dir="ltr" role="presentation">EU4 and the UK - 17%</li>
<li dir="ltr" role="presentation">Japan - 6%</li>
<li dir="ltr" role="presentation">Current GvHD prophylaxis is limited by suboptimal efficacy, particularly in high-risk transplant settings, and is associated with significant long-term toxicities.</li>
<li dir="ltr" role="presentation">The absence of targeted, durable immune tolerance strategies continues to constrain progress, underscoring the need for safer and more precise prophylactic approaches.</li>
<li dir="ltr" role="presentation">The GvHD therapeutic landscape is increasingly shaped by targeted and cell-based therapies, with key agents such as ruxolitinib (JAKAFI/JAKAVI), ibrutinib (IMBRUVICA), and remestemcel-L (RYONCIL/TEMCELL HS) playing a central role in driving market dynamics across the 7MM.</li>
<li dir="ltr" role="presentation">In 2025, ruxolitinib generated the highest revenue, followed by REZUROCK.</li>
<li dir="ltr" role="presentation">Market growth is anticipated with the introduction of emerging therapies, leading to expansion throughout the forecast period (2026&ndash;2036).</li>
</ul>
<h3 dir="ltr"><strong>Graft Versus Host Disease Market Drivers</strong></h3>
<ul>
<li dir="ltr" role="presentation">Rising incidence of hematologic malignancies is increasing the demand for transplant-related therapies.</li>
<li dir="ltr" role="presentation">Growing adoption of allogeneic stem cell transplantation is significantly contributing to the expanding patient pool.</li>
<li dir="ltr" role="presentation">Increasing awareness and early diagnosis are improving treatment accessibility and disease management.</li>
<li dir="ltr" role="presentation">Strong pipeline development and ongoing clinical trials are accelerating innovation in GvHD therapeutics.</li>
</ul>
<h3 dir="ltr"><strong>Graft Versus Host Disease Market Barriers</strong></h3>
<ul>
<li dir="ltr" role="presentation">Heavy reliance on corticosteroids, with up to 50% of GvHD patients developing resistance or dependence, highlights a critical need for more durable therapies.</li>
<li dir="ltr" role="presentation">Limited understanding of chronic GvHD pathophysiology continues to hinder optimized therapeutic development.</li>
<li dir="ltr" role="presentation">Widespread use of off-label therapies without sufficient evidence creates variability in treatment approaches across institutions.</li>
<li dir="ltr" role="presentation">Long-term toxicities associated with current prophylactic regimens remain a significant clinical challenge.</li>
</ul>
<h3 dir="ltr"><strong>Emerging Graft Versus Host Disease Drugs</strong></h3>
<ul>
<li dir="ltr" role="presentation">ZEMAIRA</li>
<li dir="ltr" role="presentation">RGI-2001</li>
<li dir="ltr" role="presentation">MaaT013</li>
<li dir="ltr" role="presentation">CYP-001</li>
<li dir="ltr" role="presentation">And others</li>
</ul>
<h3 dir="ltr"><strong>Key Graft Versus Host Disease Companies</strong></h3>
<ul>
<li dir="ltr" role="presentation">CSL Behring</li>
<li dir="ltr" role="presentation">Regimmune Corporation</li>
<li dir="ltr" role="presentation">MaaT Pharma</li>
<li dir="ltr" role="presentation">Cynata Therapeutics</li>
<li dir="ltr" role="presentation">Incyte Corporation</li>
<li dir="ltr" role="presentation">AbbVie</li>
<li dir="ltr" role="presentation">Bristol Myers Squibb</li>
<li dir="ltr" role="presentation">Mesoblast</li>
<li dir="ltr" role="presentation">JCR Pharmaceuticals</li>
<li dir="ltr" role="presentation">And others</li>
</ul>

Graft Versus Host Disease Market Infographics

Graft Versus Host Disease Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.